Is there a role for potassium channel openers in neuronal ion channel disorders?

Expert Opinion on Investigational Drugs

Volumn 9, Issue 10, 2000, Pages 2269-2280

  Lawson, K ^a  

^a SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

Channelopathies; Epilepsy; Episodic ataxia; Flupirtine; Neuromyotonia; Potassium channel openers; Retigabine; Weaver

Indexed keywords

1 (2 HYDROXY 5 TRIFLUOROMETHYLPHENYL) 5 TRIFLUOROMETHYL 2(3H) BENZIMIDAZOLONE; 1 (5 CHLORO 2 HYDROXYPHENYL) 5 TRIFLUOROMETHYL 2 BENZIMIDAZOLONE; 1 ETHYL 2 BENZIMIDAZOLINONE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; APRIKALIM; AUTOANTIBODY; CALCIUM ION; CGS 7184; CHLORZOXAZONE; CROMAKALIM; DEHYDROSOYASAPONIN 1; DIAZOXIDE; DIZOCILPINE; FLUFENAMIC ACID; FLUPIRTINE; GCS 7184; GUANINE NUCLEOTIDE BINDING PROTEIN; ION CHANNEL; LIDOCAINE ETHOBROMIDE; MAXIKDIOL; MINOXIDIL; NICORANDIL; NIFLUMIC ACID; PINACIDIL; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; POTASSIUM ION; RETIGABINE; SAPONIN DERIVATIVE; SODIUM ION; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOXAZOLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATAXIA; CELL MEMBRANE DEPOLARIZATION; CONGENITAL DEAFNESS; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; EPILEPSY; GENE MUTATION; GENETIC CODE; HUMAN; LONG QT SYNDROME; MEMBRANE POTENTIAL; MOUSE; MYOKYMIA; NERVE CELL; NERVE CELL LESION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; REPOLARIZATION; REVIEW;

EID: 0033819571     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.9.10.2269     Document Type: Review

References (73)

1. Potassium channel activation: A potential therapeutic approach?
2. Ion channel genes and human neurological disease: Recent progress, prospects and challenges
3. Potassium ion channels and human disease: Phenotypes to drug targets?
4. Neurological channelopathies: Diagnosis and therapy in the millennium
5. Voltage-gated and inwardly rectifying potassium channels
6. Potassium channels. Basic aspects, functional roles and medical significance
7. + channel, a distinct member of voltage-dependent ion channels with seven N-terminal transmembrane segments (S0-S6), an extracellular N terminus and an C terminus
8. + channels
9. Cloning of a new mouse two-P domain channel subunit and a human homologue with a unique pore structure
10. Sequence and function of the two P domain potassium channels: Implications of an emerging superfamily
11. Ion channel mutations affecting muscle and brain
12. Potassium channelopathies
13. Hyperinsulinism of infancy: Towards an understanding of understanding of unregulated insulin release
14. Episodic ataxia myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1
15. Episodic ataxia results from voltage-dependent potassium channels with altered functions
16. Episodic ataxia and channelopathies
17. Ion channels and epilepsy in man and mouse
18. Seizure characteristics in chromosome 20 benign familial neonatal convulsions
19. A potassium channel mutation in neonatal human epilepsy
20. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns
21. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family
22. KCNQ2 and KCNQ3 potassium channel subunits: Molecular correlates of the M-channel
23. Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy
24. A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia Type 1 and sometimes partial epilepsy
25. Synaptic plasticity in kindling
26. + channels of peripheral nerves
27. Strength-duration properties of peripheral nerve in acquired neuromyotonia
28. Potassium current suppression in patients with peripheral nerve hyperexcitability
29. Pathogenic autoantibodies to neuronal proteins in neurological disorders
30. + channel and rescue of weaver granule cells
31. A cell cycle alteration precedes apoptosis of granule cell precursor in the weaver mouse cerebellum
32. A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation
33. + channel proteins GIRK1 and GIRK2 and their altered expression in weaver brain
34. In situ hybridization analysis of GIRK2 expression in the developing central nervous system in normal and weaver mice
35. +-dependent inhibition in weaver hippocampus
36. The weaver mutation changes the ion selectivity of the affected inwardly rectifying potassium channel GIRK2
37. Potassium channel openers as potential therapeutic weapons in ion channel disease
38. Toward understanding the assembly and structure of K(ATP) channels
39. + channels
40. Identification of the potassium channel opener site on sulphonylurea receptors
41. Calcium activated potassium channels
42. Pharmacology of voltage-gated and calcium-activated potassium channels
43. Novel and potent BK channel openers: CGS 7181 and its analogs
44. Pharmacology of high-conductance calcium-activated potassium channels
45. High-conductance calcium-activated potassium channels in rat brain: Pharmacology, distribution and subunit composition
46. High conductance, calcium-activated potassium channels; structure, pharmacology and function
47. Mechanism of maki-K channel activation by dehydrosoyasaponin-I
48. Small-conductance, calcium-activated potassium channels from mammalian brain
49. + channels
50. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits
51. + channel opening effect of the anticonvulsant retigabine in PC12 cells
52. Potassium channels and neurodegenerative diseases
53. D-23129: A new anticonvulsant compound
54. D-23129: A new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures
55. 2+ model in the hippocampal slice preparation
56. Ionic channels and their regulation by G protein subunits
57. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurones
58. 2+ block via activation of voltage independent potassium channels
59. + channels by flupirtine
60. Pharmacological intervention in age-associated brain disorders by Flupirtine: Alzheimer's and prion diseases
61. Reconstitution of I(ATP): An inward rectifier subunit plus the sulfonylurea receptor
62. + channel
63. Molecular genetics of familial cardiomyopathies
64. Long-term (subacute) potassium treatment in congenital HERG-related long QT Syndrome (LQTS2)
65. Sensory neuron voltage-gated sodium channels and nociception
66. The dual modulation of GIRK1/GIRK2 channels by opioid receptor ligands
67. Antinociceptive action of epidural K(ATP) channel openers via interaction with morphine and an α2-adrenergic agonist in rats
68. Role of potassium channels in the antinociception induced by agonists of α2-adrenoceptors
69. Therapeutic applications of anti-depressant drugs in fibromyalgia syndrome
70. Treatment of fibromyalgia syndrome
71. Are there two distinct research strategies for developing biologically active molecules: Rational design and empirical selection?
72. Inducible genetic suppression of neuronal excitability